Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS 2-HS: BFB759 dose-ranging study in moderate to severe hidradenitis suppurativa
2025-522440-41-00Phase 2Authorised
- Sponsor
- Bluefin Biomedicine
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of BFB759 in hidradenitis suppurativa (HS) (3 arms), sponsored by Bluefin Biomedicine. Primary endpoint: Percent change in abscess and inflammatory nodule count at Week 16. Planned start Apr 2026; status: authorised.
02
Drugs
BFB759
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522440-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522440-41-00.